PT  - JOURNAL ARTICLE
AU  - Frederic Grabowski
AU  - Grzegorz Preibisch
AU  - Stanisław Giziński
AU  - Marek Kochańczyk
AU  - Tomasz Lipniacki
TI  - SARS-CoV-2 Variant of Concern 202012/01 has about twofold replicative advantage and acquires concerning mutations
AID  - 10.1101/2020.12.28.20248906
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.12.28.20248906
4099  - http://medrxiv.org/content/early/2021/02/21/2020.12.28.20248906.short
4100  - http://medrxiv.org/content/early/2021/02/21/2020.12.28.20248906.full
AB  - The novel SARS-CoV-2 Variant of Concern (VOC)-202012/01 (also known as B.1.1.7), first collected in United Kingdom on September 20, 2020, is a rapidly growing lineage that in January 2021 constituted 86% of all SARS-CoV-2 genomes sequenced in England. The VOC has been detected in 40 out of 46 countries that reported at least 50 genomes in January 2021. We have estimated that the replicative advantage of the VOC is in the range 1.83–2.18 [95% CI: 1.71–2.40] with respect to the 20A.EU1 variant that dominated in England in November 2020, and in range 1.65–1.72 [95% CI: 1.46–2.04] in Wales, Scotland, Denmark, and USA. As the VOC strain will likely spread globally towards fixation, it is important to monitor its molecular evolution. We have estimated growth rates of expanding mutations acquired by the VOC lineage to find that the L18F substitution in spike has initiated a substrain of high replicative advantage in relation to the remaining VOC substrains. The L18F substitution is of significance because it has been found to compromise binding of neutralizing antibodies. Of concern are immune escape mutations acquired by the VOC: E484K, F490S, S494P (in the receptor binding motif of spike) and Q677H, Q675H (in the proximity of the polybasic cleavage site at the S1/S2 boundary). These mutants may hinder efficiency of existing vaccines and expand in response to the increasing after-infection or vaccine-induced seroprevalence.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNorwegian Financial Mechanism GRIEG‐1 grant 2019/34/H/NZ6/00699 (operated by the National Science Centre Poland).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This theoretical study is based on data published by GISAID and GOV.UKAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study are referenced and gathered in the supplementary data set S1. GISAID: www.gisaid.org; UK.GOV: https://coronavirus.data.gov.uk/details/cases